Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease
Objective: To assess if a microglial modulator, Glatiramer Acetate (GA), can restore loss of striatal dopamine (DA) and behavioral deficits following progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)…Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease
Objective: Non-dopaminergic protein drug targets are of high interest to develop adjuvant treatments for currently insufficiently addressed symptoms of PD. RGS4, a regulator of G-protein…Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease
Objective: To assess the therapeutic potential of chronic vagus nerve stimulation (VNS) to attenuate the behavioral and neuronal deficits observed in Parkinson's disease (PD) by…Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease
Objective: Identify magnetic resonance imaging (MRI) biomarkers of nigrostriatal neurodegeneration in early-stage drug-naïve Parkinson's disease (PD). Background: Diffusion tensor imaging (DTI) is an MRI technique…The study of clinical outcome of deep brain stimulation for the idiopathic Parkinson’s disease at 6 months follow-up
Objective: The aim of this study was to assess the motor and psychiatric outcomes at 6 months after subthalamic nucleus deep brain stimulation (STN-DBS) in…Dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behaviour disorder
Objective: To assess the loss of dorsolateral nigral hypersensitivity (DNH), which seems to correspond to nigrosome-1, using susceptibility-weighted imaging (SWI) at 3.0 Tesla (T) in…
- « Previous Page
- 1
- …
- 8
- 9
- 10